The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02267200|
Recruitment Status : Completed
First Posted : October 17, 2014
Last Update Posted : November 22, 2016
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||The Screening and Analysis of Plasma Biomarkers in Irreversible Pulmonary Arterial Hypertension Associated With Congenital Heart Disease|
|Study Start Date :||October 2014|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||September 2016|
reversible PAH group
reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
irreversible PAH group
irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
- the number of Circulation endothelial cells and the detective count of microRNAs [ Time Frame: 6 months after corrective surgery ]the number of Circulation endothelial cells and the detective count of microRNAs in the biomarkers in both groups differd significantly.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02267200
|Shanghai Children's Medical Center|
|Shanghai, Shanghai, China, 200127|
|Principal Investigator:||Zhuoming Xu, Ph D||Shanghai Jiao Tong University School of Medicine|